AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

Early TNBC Efficacy Signs From Datopotamab Deruxtecan

 
• By Alaric DeArment
Doctor with Mammography - Image
AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan shows early efficacy in triple-negative breast cancer • Source: Shutterstock

More from Clinical Trials

More from R&D